BRIEF-Sanofi’s Sarclisa Subcutaneous Formulation Approved In Japan For Patients With Multiple Myeloma

June 19 (Reuters) - Sanofi SA SASY.PA:

  • PRESS RELEASE: SANOFI’S SARCLISA SUBCUTANEOUS FORMULATION APPROVED IN JAPAN FOR PATIENTS WITH MULTIPLE MYELOMA

  • APPROVAL BASED ON IRAKLIA PHASE 3 STUDY SHOWING NON-INFERIOR EFFICACY TO IV

  • CIRCLIQ ON-BODY INJECTOR FOR SARCLISA SC UNDER REVIEW IN JAPAN

  • SARCLISA SC VIA OBI PLUS PD SHOWS 71.1% ORR IN R/R MM

Source text: nGNXbmwK8R

Further company coverage: SASY.PA


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.